Dermira Inc (NASDAQ:DERM) – Investment analysts at Leerink Swann lowered their FY2022 earnings estimates for Dermira in a research note issued on Friday. Leerink Swann analyst S. Fernandez now anticipates that the biopharmaceutical company will post earnings per share of $2.40 for the year, down from their prior estimate of $2.42. Leerink Swann has a “Outperform” rating and a $48.00 price target on the stock.
Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.09). The company had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%.
Shares of Dermira (NASDAQ:DERM) traded up $0.33 on Monday, hitting $27.27. 546,900 shares of the stock were exchanged, compared to its average volume of 681,350. The firm has a market capitalization of $1,126.68, a price-to-earnings ratio of -3.71 and a beta of 0.75. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.28 and a quick ratio of 5.28. Dermira has a 1-year low of $21.35 and a 1-year high of $38.75.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jennison Associates LLC increased its stake in Dermira by 0.3% in the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after acquiring an additional 7,746 shares during the period. Vanguard Group Inc. increased its stake in Dermira by 9.8% in the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after acquiring an additional 125,157 shares during the period. Millennium Management LLC bought a new stake in Dermira in the fourth quarter valued at about $25,084,000. Franklin Resources Inc. bought a new stake in Dermira in the fourth quarter valued at about $24,820,000. Finally, State Street Corp increased its stake in Dermira by 38.4% in the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after acquiring an additional 228,093 shares during the period. 95.27% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Eugene A. Bauer sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $28.55, for a total value of $85,650.00. Following the sale, the insider now owns 5,802 shares of the company’s stock, valued at $165,647.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Christopher M. Griffith sold 18,458 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The disclosure for this sale can be found here. In the last three months, insiders sold 34,258 shares of company stock worth $935,153. 13.30% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3228720/fy2022-eps-estimates-for-dermira-inc-derm-decreased-by-leerink-swann.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.